ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,070.55
1.20%
US Tech 100
17,095.60
2.05%
Dow Jones
38,503.69
0.69%
Brent Oil
87.565
0.00%
Bitcoin
66,734.93
0.49%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Celcuity Inc (CELC) Quote

Celcuity Inc

Celcuity Inc (CELC)

NASDAQ
17.24
-0.30
(-1.71%)
Closed April 24 4:00PM
Delayed by 15 minutes
17.24
0.00
(0.00%)
After Hours: 5:30PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
17.24
Bid
9.61
Ask
23.52
Volume
90,649
17.18 Day's Range 18.21
8.389 52 Week Range 22.188
Market Cap
417.746M
Previous Close
17.54
Open
17.56
Last Trade
88
@
17.24
Last Trade Time
Financial Volume
$ 1,587,581
VWAP
17.5135
Average Volume (3m)
224,398
Shares Outstanding
24,203,156
Dividend Yield
-
PE Ratio
-6.55
Earnings Per Share (EPS)
-2.64
Revenue
-
Net Profit
-63.78M

About Celcuity Inc

Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered ... Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
www.celcuity.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Celcuity Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker CELC. The last closing price for Celcuity was $17.54. Over the last year, Celcuity shares have traded in a share price range of $ 8.389 to $ 22.188.

Celcuity currently has 24,203,156 shares outstanding. The market capitalization of Celcuity is $417.75 million. Celcuity has a price to earnings ratio (PE ratio) of -6.55.

CELC Latest News

More News

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...

April 04 2024
GlobeNewswire Inc.

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical...

March 27 2024
GlobeNewswire Inc.

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...

March 20 2024
GlobeNewswire Inc.

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...

March 06 2024
GlobeNewswire Inc.

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...

February 28 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

February 23 2024
Edgar (US Regulatory)

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first...

February 22 2024
GlobeNewswire Inc.

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...

February 20 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.69-3.8482989403217.9318.2116.1720595517.16581572CS
4-0.57-3.2004491858517.8122.18816.1723257219.17769393CS
122.2715.163660654614.9722.18813.7422439817.73822011CS
267.170.019723865910.1422.1889.3616922316.39252252CS
527.5778.28335056889.6722.1888.38912390914.49065031CS
156-7.76-31.042533.014.818386014.58570351CS
260-3.71-17.708830548920.9533.014.037370516.39834966CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NIVFNewGenIvf Group Ltd
$ 2.23
(74.22%)
137.08M
MTCMMTec Inc
$ 2.24
(43.59%)
6.07M
OPRTOportun Financial Corporation
$ 3.16
(40.44%)
11.71M
SHIMShimmick Corporation
$ 3.05
(35.56%)
1.19M
HKITHitek Global Inc
$ 1.35
(32.35%)
411.78k
ABEOAbeona Therapeutics Inc
$ 3.39
(-53.94%)
5.51M
GWAVGreenwave Technology Solutions Inc
$ 0.0696
(-44.89%)
37.05M
LICNLichen China Limited
$ 0.56
(-42.19%)
6.61M
MLECMoolec Science SA
$ 1.71
(-30.77%)
3.16M
VAXXVaxxinity Inc
$ 0.1971
(-26.89%)
2.11M
CYNCYNGN Inc
$ 0.113
(-6.61%)
326.58M
PEGYPineapple Energy Inc
$ 0.0561
(22.49%)
185.74M
SQQQProShares UltraPro Short QQQ
$ 11.91
(-4.49%)
139.15M
NIVFNewGenIvf Group Ltd
$ 2.23
(74.22%)
137.08M
TSLATesla Inc
$ 144.68
(1.85%)
124.55M

CELC Discussion

View Posts
Monksdream Monksdream 2 months ago
CELC new 52 week high
👍️0
Natureboy1 Natureboy1 3 years ago
Tiny float just under 6 million. Moves quick
👍️0
mick mick 3 years ago
A.H. ACTED LIKE HALT IN TRADING 'Celcuity' $CELE
👍️0
mick mick 3 years ago
I HAD TO DO SAME 'Celcuity' NEED QUOTES HERE $CELC
👍️0
Natureboy1 Natureboy1 3 years ago
Is that why I had to call the broker to purchase yesterday?
👍️0
Natureboy1 Natureboy1 3 years ago
Looks like you’ve already 5x’d your investment.
👍️0
Natureboy1 Natureboy1 3 years ago
Starting to move now. . You’ve been ahead of the curve.
👍️0
mick mick 3 years ago
yes yes yes 'Celcuity' need quotes asked but here yet
👍️0
Natureboy1 Natureboy1 3 years ago
Huge news today. Pfizer is a giant.
👍️0
mick mick 3 years ago
dis 'Celcuity' could $100 plus pps my friend we quotes i asked to no avail

but they are trying 'Celcuity' $CELC
👍️0
Werbe Werbe 3 years ago
👍️0
mick mick 3 years ago
[-chart]www.stockscores.com/chart.asp?TickerSymbol=CELC&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]



👍️0
mick mick 3 years ago
I DON''T SEE DA CHART Celcuity
👍️0
mick mick 3 years ago
New board. Celcuity


Future could be very promising on this one.
Any thoughts out there ?
👍️0
mick mick 3 years ago
ARE VERY RIGHT MY FRIEND 'Celcuity'
👍️0
Werbe Werbe 4 years ago
Huge sleeper here, easy x2 or x3 @ these levels IMO.

Expect to announce new clinical trial collaborations with pharmaceutical companies and trial sponsors by the end of 2020 -
👍️0
Hawkeye_tt Hawkeye_tt 6 years ago
Nice chart.
Moving w/ Vol.

Trade on...

Hawk
👍️0
Hawkeye_tt Hawkeye_tt 6 years ago
New board. Future could be very promising on this one.
Any thoughts out there ?

Hawk
👍️0

Your Recent History

NASDAQ
CELC
Celcuity
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved